🔔Join APTI PLUS Prelims Mirror 2026 | All India Open Mock Test Series on 12th April, 26th April & 3rd May 2026 |Register Now!
India is debating the introduction of data exclusivity in pharmaceuticals, a regulatory protection that can delay the entry of generic drugs even after patent expiry. While the move is projected as a way to attract investment and support innovation, it raises serious concerns for India’s generics-driven pharmaceutical industry and access to affordable medicines. In the absence of any international obligation under WTO-TRIPS, the policy choice involves balancing innovation incentives with public health priorities and preserving India’s role as the pharmacy of the developing world.
Click to View MoreIndia's pharmaceutical industry, known as the 'pharmacy of the world', has transformed affordable generic medicines into a global public good. By leveraging unique intellectual property laws and cost-effective manufacturing, India has broken monopolies on life-saving drugs like HIV/AIDS and COVID-19, redefining global health equity.
Click to View More
© 2026 iasgyan. All right reserved
